Z

Zhejiang Xianju Pharmaceutical Co Ltd
SZSE:002332

Watchlist Manager
Zhejiang Xianju Pharmaceutical Co Ltd
SZSE:002332
Watchlist
Price: 10.37 CNY 0.19% Market Closed
Market Cap: 10.3B CNY
Have any thoughts about
Zhejiang Xianju Pharmaceutical Co Ltd?
Write Note

Income Statement

Earnings Waterfall
Zhejiang Xianju Pharmaceutical Co Ltd

Revenue
4.1B CNY
Cost of Revenue
-1.9B CNY
Gross Profit
2.3B CNY
Operating Expenses
-1.5B CNY
Operating Income
714.2m CNY
Other Expenses
-92.5m CNY
Net Income
621.7m CNY

Income Statement
Zhejiang Xianju Pharmaceutical Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024
Revenue
Revenue
2 408
N/A
2 471
+3%
2 473
+0%
2 461
0%
2 466
+0%
2 480
+1%
2 441
-2%
2 504
+3%
2 457
-2%
2 504
+2%
2 548
+2%
2 572
+1%
2 671
+4%
2 853
+7%
3 117
+9%
3 338
+7%
3 514
+5%
3 622
+3%
3 628
+0%
3 723
+3%
3 741
+0%
3 709
-1%
3 618
-2%
3 620
+0%
3 873
+7%
4 019
+4%
4 276
+6%
4 391
+3%
4 402
+0%
4 337
-1%
4 385
+1%
4 422
+1%
4 473
+1%
4 380
-2%
4 288
-2%
4 270
0%
4 164
-2%
4 123
-1%
4 204
+2%
4 143
-1%
4 123
0%
Gross Profit
Cost of Revenue
(1 487)
(1 525)
(1 501)
(1 444)
(1 438)
(1 414)
(1 362)
(1 359)
(1 273)
(1 236)
(1 255)
(1 238)
(1 259)
(1 263)
(1 360)
(1 444)
(1 480)
(1 493)
(1 496)
(1 530)
(1 522)
(1 477)
(1 502)
(1 512)
(1 629)
(1 801)
(1 902)
(1 942)
(1 957)
(1 832)
(1 860)
(1 888)
(1 963)
(1 865)
(1 886)
(1 961)
(1 977)
(1 972)
(1 990)
(1 922)
(1 869)
Gross Profit
921
N/A
946
+3%
972
+3%
1 018
+5%
1 028
+1%
1 067
+4%
1 079
+1%
1 145
+6%
1 184
+3%
1 268
+7%
1 292
+2%
1 334
+3%
1 412
+6%
1 590
+13%
1 757
+11%
1 894
+8%
2 034
+7%
2 129
+5%
2 131
+0%
2 193
+3%
2 218
+1%
2 232
+1%
2 115
-5%
2 108
0%
2 244
+6%
2 218
-1%
2 373
+7%
2 449
+3%
2 446
0%
2 505
+2%
2 525
+1%
2 534
+0%
2 510
-1%
2 515
+0%
2 402
-4%
2 309
-4%
2 187
-5%
2 152
-2%
2 214
+3%
2 221
+0%
2 254
+1%
Operating Income
Operating Expenses
(823)
(826)
(842)
(872)
(870)
(911)
(926)
(973)
(989)
(1 079)
(1 103)
(1 099)
(1 148)
(1 250)
(1 335)
(1 450)
(1 545)
(1 653)
(1 610)
(1 652)
(1 639)
(1 645)
(1 553)
(1 501)
(1 584)
(1 561)
(1 635)
(1 707)
(1 721)
(1 803)
(1 791)
(1 802)
(1 762)
(1 802)
(1 693)
(1 629)
(1 556)
(1 520)
(1 575)
(1 556)
(1 539)
Selling, General & Administrative
(812)
(717)
(829)
(852)
(849)
(802)
(906)
(948)
(967)
(970)
(1 087)
(1 083)
(1 110)
(1 146)
(1 301)
(1 419)
(1 499)
(1 464)
(1 484)
(1 497)
(1 482)
(1 422)
(1 370)
(1 305)
(1 382)
(1 327)
(1 417)
(1 472)
(1 477)
(1 550)
(1 576)
(1 590)
(1 560)
(1 542)
(1 448)
(1 362)
(1 294)
(1 262)
(1 309)
(1 289)
(1 260)
Research & Development
0
(88)
0
0
0
(87)
0
0
0
(87)
0
0
(22)
(88)
0
0
(36)
(138)
(118)
(161)
(169)
(198)
(210)
(215)
(228)
(200)
(232)
(232)
(232)
(231)
(249)
(241)
(237)
(258)
(251)
(263)
(255)
(253)
(288)
(293)
(306)
Depreciation & Amortization
0
(17)
0
0
0
(19)
0
0
0
(20)
0
0
0
(20)
0
0
0
(49)
0
0
0
(51)
0
0
0
(50)
0
0
0
(49)
0
0
0
(47)
0
0
0
(48)
0
0
0
Other Operating Expenses
(11)
(4)
(13)
(20)
(21)
(3)
(21)
(26)
(22)
(3)
(14)
(16)
(15)
4
(35)
(31)
(10)
(2)
(9)
6
12
26
28
20
26
16
14
(4)
(12)
27
34
29
35
45
7
(4)
(7)
44
22
25
27
Operating Income
98
N/A
120
+22%
130
+9%
146
+12%
158
+8%
156
-2%
153
-2%
172
+12%
195
+14%
188
-3%
189
+1%
235
+24%
264
+12%
340
+29%
422
+24%
443
+5%
489
+10%
476
-3%
521
+9%
541
+4%
580
+7%
587
+1%
563
-4%
608
+8%
660
+9%
657
0%
738
+12%
742
+1%
725
-2%
702
-3%
734
+5%
732
0%
749
+2%
713
-5%
710
0%
680
-4%
631
-7%
631
+0%
639
+1%
665
+4%
714
+7%
Pre-Tax Income
Interest Income Expense
(50)
(51)
(54)
(56)
(50)
(38)
(39)
(31)
(29)
(10)
(9)
(22)
(25)
(42)
(67)
(72)
(71)
(43)
(66)
(43)
(41)
(47)
(40)
(55)
(62)
(59)
(72)
(64)
(44)
36
32
82
97
38
79
50
45
19
38
37
18
Non-Reccuring Items
0
0
0
0
0
(2)
0
0
0
(2)
0
(2)
(2)
0
0
2
2
(5)
(0)
0
(0)
(5)
0
0
0
(2)
(1)
(1)
5
(4)
0
15
9
127
90
90
90
(4)
0
0
(1)
Gain/Loss on Disposition of Assets
0
(1)
0
0
0
(0)
0
0
(0)
0
(1)
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
5
5
5
5
(1)
12
13
8
5
7
4
5
10
(6)
(8)
(6)
(9)
2
(1)
(1)
(9)
(8)
(15)
(16)
(10)
25
23
24
24
(9)
(34)
(33)
(27)
(6)
(1)
(0)
(5)
(4)
(7)
(5)
(6)
Pre-Tax Income
52
N/A
73
+40%
81
+10%
95
+18%
108
+13%
128
+19%
127
-1%
149
+17%
171
+15%
183
+7%
184
+0%
217
+18%
247
+14%
292
+18%
347
+19%
368
+6%
411
+12%
430
+5%
454
+5%
497
+10%
529
+6%
527
0%
508
-4%
537
+6%
588
+10%
621
+6%
690
+11%
701
+2%
709
+1%
726
+2%
732
+1%
795
+9%
827
+4%
872
+5%
877
+1%
819
-7%
761
-7%
642
-16%
670
+4%
697
+4%
726
+4%
Net Income
Tax Provision
(11)
(24)
(24)
(27)
(27)
(23)
(21)
(30)
(36)
(37)
(37)
(45)
(48)
(62)
(81)
(89)
(103)
(85)
(84)
(89)
(88)
(85)
(77)
(75)
(93)
(92)
(110)
(111)
(98)
(108)
(105)
(129)
(138)
(125)
(123)
(95)
(74)
(80)
(81)
(88)
(93)
Income from Continuing Operations
42
49
56
68
80
105
105
119
134
146
147
172
200
230
266
280
308
345
370
408
442
443
431
461
495
529
579
589
611
618
627
667
690
747
755
725
687
562
589
609
633
Income to Minority Interest
3
8
4
2
8
2
3
5
0
(0)
2
(3)
(13)
(24)
(35)
(31)
(31)
(44)
(51)
(57)
(61)
(32)
(12)
(20)
(17)
(25)
(31)
(16)
(6)
(2)
6
6
(4)
2
0
(5)
5
1
(8)
(8)
(11)
Net Income (Common)
45
N/A
57
+26%
60
+6%
71
+17%
88
+24%
107
+21%
108
+2%
123
+13%
135
+10%
146
+9%
149
+2%
168
+13%
187
+11%
207
+11%
231
+12%
249
+8%
277
+11%
301
+9%
319
+6%
352
+10%
381
+8%
410
+8%
420
+2%
442
+5%
478
+8%
505
+6%
548
+9%
573
+5%
605
+6%
616
+2%
633
+3%
673
+6%
686
+2%
749
+9%
755
+1%
720
-5%
692
-4%
563
-19%
581
+3%
601
+3%
622
+3%
EPS (Diluted)
0.06
N/A
0.07
+17%
0.08
+14%
0.09
+13%
0.11
+22%
0.12
+9%
0.12
N/A
0.13
+8%
0.14
+8%
0.16
+14%
0.17
+6%
0.19
+12%
0.21
+11%
0.23
+10%
0.25
+9%
0.27
+8%
0.3
+11%
0.33
+10%
0.35
+6%
0.39
+11%
0.42
+8%
0.45
+7%
0.46
+2%
0.48
+4%
0.52
+8%
0.51
-2%
0.55
+8%
0.6
+9%
0.61
+2%
0.62
+2%
0.64
+3%
0.68
+6%
0.69
+1%
0.76
+10%
0.76
N/A
0.73
-4%
0.7
-4%
0.57
-19%
0.59
+4%
0.61
+3%
0.63
+3%

See Also

Discover More